Holen Sie sich die Stockscreener-App
120.67
2.96%
-3.68
Handel nachbörslich:
120.50
-0.17
-0.14%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$124.35
Offen:
$124.08
24-Stunden-Volumen:
6.26M
Relative Volume:
0.93
Marktkapitalisierung:
$149.71B
Einnahmen:
$29.05B
Nettoeinkommen (Verlust:
$8.11B
KGV:
18.69
EPS:
6.4563
Netto-Cashflow:
$9.16B
1W Leistung:
-1.69%
1M Leistung:
-0.43%
6M Leistung:
+8.65%
1J Leistung:
+35.37%
1-Tages-Spanne:
$119.93
$125.11
1-Wochen-Bereich:
$116.88
$125.11
52-Wochen-Spanne:
$88.57
$128.70
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Vergleichen Sie GILD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
120.67 | 154.28B | 29.05B | 8.11B | 9.16B | 6.4563 |
|
LLY
Lilly Eli Co
|
1,085.19 | 991.76B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
205.75 | 499.90B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
224.13 | 412.54B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
110.99 | 269.55B | 63.90B | 19.05B | 13.05B | 7.5596 |
|
NVS
Novartis Ag Adr
|
141.46 | 272.43B | 54.45B | 14.42B | 17.15B | 7.333 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead Names Wettan Executive Vice President - BioXconomy
Gilead (GILD) Recalls Veklury Due to Contaminant Concerns - GuruFocus
What is the fair value of Gilead Sciences Inc. stock now2025 Top Gainers & Risk Controlled Stock Alerts - ulpravda.ru
The Escalator: Argenx, Gilead Sciences, Bristol Myers Squibb and more - Medical Marketing and Media
Gilead Sciences, Inc. $GILD Holdings Decreased by Commonwealth Equity Services LLC - MarketBeat
Today's Analyst Action: Citigroup Raises Gilead Sciences (GILD) Price Target | GILD Stock News - GuruFocus
GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies - Benzinga
UBS Raises Gilead Sciences (GILD) Price Target to $145 and Upgra - GuruFocus
Gilead Sciences (NASDAQ:GILD) Given Buy Rating at UBS Group - MarketBeat
Assessing Gilead Sciences (GILD) Valuation After Recent Share Price Momentum - Yahoo! Finance Canada
UBS raises Gilead Sciences stock price target to $145 on HIV drug outlook - Investing.com India
Gilead Sciences (NASDAQ:GILD) Nasdaq 100 Index Biopharma Scale - Kalkine Media
Key facts: Citi names Gilead Sciences a top biopharma pick; margin concerns rise - TradingView — Track All Markets
Assessing Gilead Sciences (GILD) Valuation After Mixed Near Term Returns And 9.4% Undervaluation Estimate - simplywall.st
Gilead Keeps Dealing With $300M OncoNano Drug Delivery Cancer Pact - BioSpace
OncoNano Medicine partners with Gilead to test drug delivery tech - Investing.com
OncoNano Medicine partners with Gilead to test drug delivery tech By Investing.com - Investing.com Canada
OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead’s Drug Candidate - Yahoo Finance
Robeco Institutional Asset Management B.V. Purchases 59,295 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q3 Earnings? - Yahoo Finance
Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Repare Therapeutics Sells RP-3467 Cancer Program Assets to Gilead for Up to $30 Million - TipRanks
11,480 Shares in Gilead Sciences, Inc. $GILD Bought by TriaGen Wealth Management LLC - MarketBeat
Railway Pension Investments Ltd Purchases 42,200 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
The Truth About Gilead Sciences Inc (GILD): Hidden Giant or Boomer Stock Trap? - AD HOC NEWS
Gateway Investment Advisers LLC Raises Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
SteelPeak Wealth LLC Sells 94,279 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Purchased by Asset Management One Co. Ltd. - MarketBeat
Verity & Verity LLC Has $30.05 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Stock Position Lifted by Allspring Global Investments Holdings LLC - MarketBeat
Gilead Sciences (NASDAQ:GILD) Upgraded to "Strong-Buy" at Wall Street Zen - MarketBeat
Former Gilead exec who oversaw $20B in drug sales takes global role at autoimmune disease company - The Business Journals
AbbVie, Gilead gift themselves clinical-stage cancer drugs via licensing deals - Fierce Biotech
Miracle Mile Advisors LLC Buys 25,117 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
CapWealth Advisors LLC Has $27.04 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Bank Pictet & Cie Europe AG Boosts Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Here's How Much $1000 Invested In Gilead Sciences 15 Years Ago Would Be Worth Today - Sahm
Gilead Sciences Q3 EPS Forecast Raised by Zacks Research - MarketBeat
Morgan Stanley Expects Gilead Sciences (GILD) to Thrive as Biopharma Policy Uncertainties Fade in 2026 - Finviz
What's Driving the Market Sentiment Around Gilead Sciences Inc? - Benzinga
Los Angeles Capital Management LLC Purchases 1,223,895 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Lee Johnson Capital Management LLC Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Ascent Group LLC Buys 11,926 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead (GILD) Reaches Pricing Agreement with US Government to Lower Drug Costs - Finviz
Why Gilead Sciences (GILD) Dipped More Than Broader Market Today - sharewise.com
Insider Sell: Daniel O'Day Sells 10,000 Shares of Gilead Sciences Inc (GILD) - GuruFocus
Gilead (GILD) reaches pricing agreement with US government to lower drug costs - MSN
Daniel Patrick O'day Sells 10,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Diversified Trust Co Increases Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Abacus FCF Advisors LLC Reduces Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.04%
3.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):